- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference:
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – ALAMEDA, Calif. --(BUSINESS WIRE)--May 21, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX ® (cabozantinib), and its
– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial – ALAMEDA, Calif. --(BUSINESS WIRE)--May 19, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026:
- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2027 - - Conference Call and Webcast Today
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m.
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 24, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46 th Annual Health Care
– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of
– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results from the phase 3 STELLAR-303 pivotal trial, in which zanzalintinib in combination with atezolizumab improved median overall survival and significantly reduced the risk of
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday,
– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy – ALAMEDA, Calif. & AUSTIN, Texas --(BUSINESS WIRE)--Jan. 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA
– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 6, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey , Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the J.P.
- Event to Review R&D Progress and Outline Exelixis’ Strategy for Building Next-generation Oncology Franchises - ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 3, 2025-- Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation